ArticleJournal of managed care & specialty pharmacy2025
Prevalence of obesity-related multimorbidity and its health care costs among adults in the United States.
Article in Journal of managed care & specialty pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Peripheral Nerve Blocks Modulate the Pain-Mood Relationship in Bariatric Surgery: A Secondary Analysis of a Randomized, Controlled Trial.Drug design, development and therapy · 2026Trial
- Clinical and Economic Burden of Obesity and Cardiovascular Disease Among Medicare Fee-For-Service Beneficiaries.Diabetes, obesity & metabolism · 2026Article
- Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling Approach.PharmacoEconomics · 2026Article
- Understanding the socio-economic and health burden of obesity: a 10-year retrospective analysis of population-wide administrative healthcare data.Reviews in endocrine & metabolic disorders · 2026Review
- Prevalence of Obesity and Related Conditions and GLP-1 Use in Medicare Fee-for-Service Beneficiaries.Diabetes, obesity & metabolism · 2026Article
- Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice-Insights From the AROS Database.Diabetes, obesity & metabolism · 2026Article
- Obesity in Late Adolescence and Healthcare Costs in Young to Mid-Adulthood.Diabetes, obesity & metabolism · 2026Article
- Lifestyle factors impact sperm microbiota and are associated with biological and clinical issues in infertile patients undergoing assisted reproductive technologies, a proof-of-concept study.Scientific reports · 2026Article
- 2025 Obesity Fact Sheet for Korea: Prevalence of Obesity, Abdominal Obesity from 2014 to 2023 and Prevalence of Chronic Disease by Obesity Status.Journal of obesity & metabolic syndrome · 2026Article
- Article
- Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure.International journal of molecular sciences · 2026Review
- The Influence of BMI on Mortality and Clinical Outcomes After Burns.European burn journal · 2026Article
- Developing evidence-informed pathways for long-term engagement in cycling for the United States.Frontiers in sports and active living · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOverweight and obesity are associated with many obesity-related complications (ORCs) and drive increased health care costs. However, data on the impact of obesity severity on multimorbidity and the effect of multimorbidity on cost and health care resource utilization (HCRU) in people with overweight or obesity are limited.
objectiveTo determine in reference to obesity-related multimorbidity (1) if prevalence increases with higher levels of weight class, (2) if higher levels of weight class are associated with an increased risk of multimorbidity at an earlier age, and (3) how HCRU and health care costs are impacted, including if there is a beyond-additive effect on ORC-related costs.
methodsThis retrospective cross-sectional study used linked electronic health records (EHRs) and insurance claims from Optum's de-identified Market Clarity Data. Costs were considered from January 1 to December 31, 2019. Patients continuously insured in 2018 and 2019 with at least 1 recorded body mass index (BMI) in 2019 were included. The presence of 17 prespecified ORCs was determined from the database based on the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes. ORC-related medical services costs were based on ICD-10-CM diagnosis codes in the primary position; pharmacy costs were based on National Drug Codes. Total health care costs were the sum of medical services and pharmacy costs. Weight classes were derived from the patients' median BMI in the EHR in 2019.
resultsThe prevalence of multimorbidity increased with increasing weight levels (12.3% in overweight and 33.4% in class 3 obesity for ages 19-40 years; 41.5% and 66.6% for ages 41-65 years; and 70.6%-85.9% for age ≥65 years). Ages for predicted 50% risk of having at least 2 ORCs were 59, 54, 49, and 43 years among patients with overweight and obesity classes 1, 2, and 3, respectively. The mean effect of multimorbidity on ORC-related costs was beyond additive in those with obesity, such that the ORC-related costs were about $1,082 (151%), $1,696 (218%), and $2,433 (264%) for class 1, class 2, and class 3 obesity, respectively. This effect was not present for overweight, for which the cost was $310 (42%). Individuals with multimorbidity had higher odds of emergency department visits (odds ratio [OR] = 1.74; 95% CI = 1.73-1.76) and inpatient hospitalization (OR = 3.32; 95% CI = 3.27-3.38).
conclusionsThe prevalence of obesity-related multimorbidity increased with increasing weight classes within age groups. Obesity-related multimorbidity presented at an earlier age with higher weight class, such that the predicted probability of having obesity-related multimorbidity was more than a decade younger in class 2 and class 3 obesity compared with overweight. It was associated with increased HCRU and higher-than-expected costs exceeding the sum for the ORCs. Early diagnosis and treatment of obesity may be needed to prevent or delay the onset of obesity-related multimorbidity and limit its associated health care costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.